Latest receivables for NMTC: $2.4M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
NeuroOne Medical Technologies posts a receivables of $2.4M as of March 2026. That compares with $320M in the prior-year period — down 99.2% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.
In the prior comparable period, NeuroOne Medical Technologies's receivables was $320M. The latest reading is $2.4M — a 99.2% year-over-year decrease (period ending March 2026). Use the history and growth charts on this page for a longer lookback.
Receivables is one piece of NeuroOne Medical Technologies's financial statement story. At $2.4M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.
Context for NMTC's receivables usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; NeuroOne Medical Technologies's other metric pages and overview cover the third.